



**PROTECH**

**Factsheet**

**European  
Heterosexual  
Cisgender  
Men**

# **Inject PrEP to protect?**

The first Pan European study exploring the willingness to use long-acting injectable PrEP to prevent HIV.



**Maastricht University**

# What is the PROTECT Survey?

This online survey was conducted across Europe (Oct 2023 to March 2024) and sought to uncover who may benefit from the innovation that is long-acting injectable PrEP.

The European Commission (EC) has authorized Apretude ® (cabotegravir long-acting [LA] injectable and tablets) for HIV prevention.


It is important for health services and policy makers to understand who may be interested in taking long-acting injectable PrEP so that resources can be most effectively allocated.

**This factsheet reports on data from the PROTECT Survey collected from European Heterosexual Cisgender Men, who report being HIV-negative, N= 2547.**


# Heterosexual Cisgender Men

2547

## SURVEYS COLLECTED BY COUNTRY




## AGE




# Heterosexual Cisgender Men

2547

## MIGRANT STATUS




## RELATIONSHIP STATUS




# Heterosexual Cisgender Men **2547**

## CHEMSEX (in the past 6 months)



## NUMBER OF SEXUAL PARTNERS (in the past 6 months)




# Heterosexual Cisgender Men

2547

Example of campaign image



## HIV TESTING FREQUENCY



- More than every 6 months: 27
- Every 6 months: 47
- Less than once a year: 0
- Once a year: 168
- Never: 2305


## ORAL PrEP USE HISTORY & CURRENT PrEP REGIMEN

- Naive: 2542
- Current: 2
- Former: 3

Naive: 2542

# Heterosexual Cisgender Men **2547**

## AWARENESS OF ORAL PrEP



## Example of campaign image



# Barriers to oral PrEP use

- **0.6% of the heterosexual cisgender men said:**
  - Oral PrEP was too costly (either the pills or the tests associated with PrEP use)
- **1.2% of the heterosexual cisgender men said :**
  - Their healthcare provider did not offer oral PrEP to them
- **0.3% of the heterosexual cisgender men said:**
  - There was a waiting list at their healthcare provider for oral PrEP and the service was not available
- **0.4% of the heterosexual cisgender men said:**
  - The procedure took too long to obtain oral PrEP when they needed it






# Long-acting PrEP: interest and intention

**11%**

are interested in using LA-PrEP if it becomes available.\*

**8%**

intend to use LA-PrEP if it becomes available.\*



# Summary & Contact Information

## SUMMARY

- Few heterosexual cisgender men across Europe are aware of PrEP and have taken up oral PrEP. Barriers to starting PrEP still exist.
- Interest and intention to use LA-PrEP among heterosexual cisgender men across Europe is low and gaps exist between interest to use LA-PrEP and current oral PrEP use.
- LA-PrEP may provide an opportunity for greater HIV prevention in Europe

## CONTACT INFORMATION

- Prof. Dr. Kai J. Jonas  
Email: [kai.jonas@maastrichtuniversity.nl](mailto:kai.jonas@maastrichtuniversity.nl)
- Dr. Johann Kolstee  
Email: [johann.kolstee@maastrichtuniversity.nl](mailto:johann.kolstee@maastrichtuniversity.nl)
- Maastricht University postal address  
P.O. Box 616, 6200 MD Maastricht, The Netherlands